T1	Participants 230 422	Eligible patients (1439) were randomized according to stage (I-IV) and histology (favorable [FH] or unfavorable [UH]), and contributed data to survival and relapse-free survival (RFS) analyses
T2	Participants 147 168	low-risk patients and
T3	Participants 42 75	Third National Wilms' Tumor Study
